Evidence map›Paper›PMID 42357418›Full record

ArticleMolecules (Basel, Switzerland)2026

Toward Rational Design of PFAS-Extracting Deep Eutectic Solvents: Bifunctional Architectures, Leaching Constraints, and Scalability Targets.

Santiago Aparicio

Abstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Santiago AparicioDepartment of Chemistry, University of Burgos, 09001 Burgos, Spain.ORCID 0000-0001-9996-2426

Funding

Agencia Estatal de Investigación NADESforPFAS, Ref.: PID2022-142405OB-I00
6 · The paper itself

Abstract

Per- and polyfluoroalkyl substances (PFASs) constitute a chemically diverse family of persistent contaminants, the regulation of which is tightening rapidly in Europe and the United States. Granular activated carbon, selective ion exchange, and pressure-driven membranes remove many long-chain PFASs, but their performance is less robust for short-chain and ultrashort species, and all generate concentrated secondary waste streams. Hydrophobic deep eutectic solvents (DESs), including natural deep eutectic solvents (NADESs), have emerged as tunable liquid extractants able to concentrate PFASs into small solvent volumes that can be regenerated or coupled to destruction. This perspective differs from existing DES-PFAS reviews by converting qualitative solvent-selection arguments into a decision framework with explicit acceptance gates: broad PFAS affinity, a component-resolved non-migration specification for treated water, viscosity and mass-transfer limits, regenerability targets, and techno-economic/life-cycle benchmarking against incumbent processes. We refine the bifunctional DES design hypothesis by separating validated regimes from unresolved cases, identifying the reliability limits of COSMO-RS, molecular dynamics, and machine-learning screening, and defining tiered reporting requirements for early-stage studies. The central message is that PFAS-extracting DES should no longer be evaluated only by single-compound removal percentages; they must be judged as integrated, closed-loop treatment materials with solvent losses, regeneration stability, destruction compatibility, cost, and environmental impacts that are quantified from the outset.

Indexed as

COSMO-RShydrophobic deep eutectic solventslife-cycle assessmentliquid–liquid extractionmolecular dynamicsnatural deep eutectic solventsPFASSafe-and-Sustainable-by-Designsolvent migrationtechno-economics

Identifiers

PMID42357418
PMCPMC13304570

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.